ES2398076T3 - Anticuerpos de alta afinidad contra el receptor de IL-6 humano - Google Patents
Anticuerpos de alta afinidad contra el receptor de IL-6 humano Download PDFInfo
- Publication number
- ES2398076T3 ES2398076T3 ES11171039T ES11171039T ES2398076T3 ES 2398076 T3 ES2398076 T3 ES 2398076T3 ES 11171039 T ES11171039 T ES 11171039T ES 11171039 T ES11171039 T ES 11171039T ES 2398076 T3 ES2398076 T3 ES 2398076T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- synthetic
- artificial sequence
- prt
- dna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000005962 receptors Human genes 0.000 title description 16
- 108020003175 receptors Proteins 0.000 title description 16
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 title description 6
- 102000052611 human IL6 Human genes 0.000 title description 6
- 230000027455 binding Effects 0.000 claims abstract description 90
- 239000000427 antigen Substances 0.000 claims abstract description 79
- 102000036639 antigens Human genes 0.000 claims abstract description 79
- 108091007433 antigens Proteins 0.000 claims abstract description 79
- 239000012634 fragment Substances 0.000 claims abstract description 59
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims abstract description 17
- 102000052623 human IL6R Human genes 0.000 claims abstract description 12
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims abstract description 11
- 241000282414 Homo sapiens Species 0.000 claims description 52
- 210000004027 cell Anatomy 0.000 claims description 45
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 102000004889 Interleukin-6 Human genes 0.000 claims description 19
- 108090001005 Interleukin-6 Proteins 0.000 claims description 19
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims description 16
- 230000001404 mediated effect Effects 0.000 claims description 14
- 241000282693 Cercopithecidae Species 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 201000010099 disease Diseases 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims description 11
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 7
- 206010003246 arthritis Diseases 0.000 claims description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 6
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 3
- 239000013604 expression vector Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 238000011084 recovery Methods 0.000 claims 1
- 108020004414 DNA Proteins 0.000 description 129
- 108090000623 proteins and genes Proteins 0.000 description 34
- 238000000034 method Methods 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 19
- 235000018102 proteins Nutrition 0.000 description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 16
- 229940100601 interleukin-6 Drugs 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 238000006467 substitution reaction Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 229920001184 polypeptide Polymers 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 8
- 210000003719 b-lymphocyte Anatomy 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 238000003018 immunoassay Methods 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 230000000903 blocking effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 239000000539 dimer Substances 0.000 description 5
- 230000028993 immune response Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108010051219 Cre recombinase Proteins 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 108060001084 Luciferase Proteins 0.000 description 3
- 241000282567 Macaca fascicularis Species 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 102000004495 STAT3 Transcription Factor Human genes 0.000 description 3
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 230000003472 neutralizing effect Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 description 2
- 101710152369 Interleukin-6 receptor subunit beta Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108010021843 fluorescent protein 583 Proteins 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- -1 phosphoryl groups Chemical group 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 206010048998 Acute phase reaction Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100338243 Caenorhabditis elegans hil-6 gene Proteins 0.000 description 1
- 101100476202 Caenorhabditis elegans mog-2 gene Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 238000012491 Luciferase Bioassay Methods 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100476480 Mus musculus S100a8 gene Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 101100029566 Rattus norvegicus Rabggta gene Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108091027981 Response element Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150099493 STAT3 gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 238000012452 Xenomouse strains Methods 0.000 description 1
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000001261 affinity purification Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000002482 oligosaccharides Polymers 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000007030 peptide scission Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000011524 similarity measure Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000012646 vaccine adjuvant Substances 0.000 description 1
- 229940124931 vaccine adjuvant Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81066406P | 2006-06-02 | 2006-06-02 | |
| US810664P | 2006-06-02 | ||
| US84323206P | 2006-09-08 | 2006-09-08 | |
| US843232P | 2006-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2398076T3 true ES2398076T3 (es) | 2013-03-13 |
Family
ID=38792460
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11171039T Active ES2398076T3 (es) | 2006-06-02 | 2007-06-01 | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
| ES07777380T Active ES2377579T3 (es) | 2006-06-02 | 2007-06-01 | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07777380T Active ES2377579T3 (es) | 2006-06-02 | 2007-06-01 | Anticuerpos de alta afinidad contra el receptor de IL-6 humano |
Country Status (34)
Families Citing this family (382)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| CA2872136C (en) | 2002-07-18 | 2017-06-20 | Merus B.V. | Recombinant production of mixtures of antibodies |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| AU2004242614B2 (en) | 2003-05-30 | 2011-09-22 | Merus N.V. | Fab library for the preparation of anti vegf and anti rabies virus fabs |
| CA2626688C (en) | 2005-10-21 | 2017-10-03 | Chugai Seiyaku Kabushiki Kaisha | Agents for treating cardiopathy |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| US9260516B2 (en) | 2006-04-07 | 2016-02-16 | Osaka University | Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor |
| MX2008014804A (es) | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| US8153128B2 (en) * | 2006-11-30 | 2012-04-10 | Medimmune Limited | Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor |
| RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
| WO2008090901A1 (ja) | 2007-01-23 | 2008-07-31 | Shinshu University | 慢性拒絶反応抑制剤 |
| WO2008144757A1 (en) * | 2007-05-21 | 2008-11-27 | Alder Biopharmaceuticals, Inc. | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US8062864B2 (en) * | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US8178101B2 (en) | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| CA2688146C (en) | 2007-05-21 | 2018-03-06 | Alder Biopharmaceuticals, Inc. | Antibodies to il-6 and use thereof |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| AU2008287037B2 (en) | 2007-08-10 | 2013-10-10 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| PE20140132A1 (es) | 2007-09-26 | 2014-02-14 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6 |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| ES2566957T3 (es) | 2007-09-26 | 2016-04-18 | Chugai Seiyaku Kabushiki Kaisha | Región constante de anticuerpo modificado |
| UA121453C2 (uk) | 2008-04-11 | 2020-06-10 | Чугей Сейяку Кабусікі Кайся | Спосіб одержання фармацевтичної композиції, яка містить антитіло |
| ES2564635T3 (es) | 2008-05-13 | 2016-03-28 | Novimmune Sa | Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos |
| AU2009248834B2 (en) * | 2008-05-23 | 2014-10-30 | Ablexis Llc | Method of generating single VL domain antibodies in transgenic animals |
| CN104906581A (zh) | 2008-06-05 | 2015-09-16 | 国立研究开发法人国立癌症研究中心 | 神经浸润抑制剂 |
| PT2147594E (pt) | 2008-06-27 | 2014-02-17 | Merus B V | Mamíferos não humanos que produzem anticorpos |
| AU2012200724B8 (en) * | 2008-09-26 | 2014-09-11 | Chugai Seiyaku Kabushiki Kaisha | Improved antibody molecules |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| CA2742786A1 (en) * | 2008-11-13 | 2010-05-20 | Femta Pharmaceuticals, Inc. | Humanized anti-il-6 antibodies |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US8323649B2 (en) * | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| BRPI1005398A2 (pt) * | 2009-02-24 | 2019-03-26 | Esbatech, An Alcon Biomedical Research Unit Llc | métodos para identificação de imunoligantes de antígenos na superfície celular. |
| CN102239181A (zh) * | 2009-02-24 | 2011-11-09 | 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 | 用于鉴定细胞表面抗原的免疫结合剂的方法 |
| WO2010106812A1 (en) * | 2009-03-19 | 2010-09-23 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical formulation containing improved antibody molecules |
| TWI682995B (zh) | 2009-03-19 | 2020-01-21 | 日商中外製藥股份有限公司 | 抗體恆定區域改變體 |
| EP2409991B1 (en) | 2009-03-19 | 2017-05-03 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| KR101470690B1 (ko) | 2009-04-10 | 2014-12-10 | 아블린쓰 엔.브이. | Ｉｌ－６ｒ에 대한 개선된 아미노산 서열 및 ｉｌ－６ｒ 관련 질환 및 질병의 치료를 위한 그를 포함하는 폴리펩티드 |
| WO2010115995A2 (en) * | 2009-04-10 | 2010-10-14 | Ablynx Nv | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| DK2564695T3 (en) | 2009-07-08 | 2015-05-26 | Kymab Ltd | Animal models and therapeutic molecules |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| MX2012004682A (es) * | 2009-10-26 | 2012-09-07 | Hoffmann La Roche | Metodo para la produccion de una inmunoglobulina glicosilada. |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| JP5909449B2 (ja) | 2009-12-10 | 2016-04-26 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 重鎖抗体を作製するマウス |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3417B1 (ar) * | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| TWI505838B (zh) | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| PL2505654T5 (pl) | 2010-02-08 | 2020-11-30 | Regeneron Pharmaceuticals, Inc. | Mysz ze wspólnym łańcuchem lekkim |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| WO2011146938A1 (en) * | 2010-05-21 | 2011-11-24 | NanoOncology, Inc. | Reagents and methods for treating cancer |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| US9539322B2 (en) | 2010-05-28 | 2017-01-10 | National University Corporation Hokkaido University | Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody |
| WO2011159938A2 (en) | 2010-06-16 | 2011-12-22 | Trellis Bioscience, Inc. | High affinity human antibodies to human cytomegalovirus (cmv) gb protein |
| NZ707327A (en) | 2010-08-02 | 2017-01-27 | Regeneron Pharma | Mice that make binding proteins comprising vl domains |
| AR083044A1 (es) | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| US9533039B2 (en) | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| US9304134B2 (en) | 2010-11-23 | 2016-04-05 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of anemia |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| KR102385507B1 (ko) | 2010-11-30 | 2022-04-12 | 추가이 세이야쿠 가부시키가이샤 | 복수 분자의 항원에 반복해서 결합하는 항원 결합 분자 |
| US20120189621A1 (en) | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
| PL2668212T3 (pl) | 2011-01-28 | 2018-08-31 | Sanofi Biotechnology | Ludzkie przeciwciała przeciwko pcsk9 do zastosowania w sposobach leczenia konkretnych grup osobników |
| LT2578688T (lt) | 2011-02-25 | 2019-11-11 | Regeneron Pharma | Adam6 pelės |
| CN103502274B (zh) * | 2011-03-03 | 2016-01-06 | 埃派斯进有限公司 | 抗-il-6受体抗体及其使用方法 |
| AU2012239382B2 (en) | 2011-04-01 | 2016-04-21 | Chugai Seiyaku Kabushiki Kaisha | Recombinant polypeptide production method |
| ES2656852T3 (es) | 2011-05-12 | 2018-02-28 | Regeneron Pharmaceuticals, Inc. | Ensayo de liberación de neuropéptidos para canales de sodio |
| AR087329A1 (es) | 2011-06-17 | 2014-03-19 | Regeneron Pharma | Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| WO2013022782A1 (en) | 2011-08-05 | 2013-02-14 | Regeneron Pharmaceuticals, Inc. | Humanized universal light chain mice |
| AU2012311286B2 (en) | 2011-09-19 | 2018-07-26 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| DK2747782T3 (en) | 2011-09-23 | 2018-04-23 | Ablynx Nv | Long-term inhibition of interleukin-6-mediated signal transmission |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| HK1200468A1 (en) | 2011-09-30 | 2015-08-07 | Regeneron Pharmaceuticals, Inc. | Anti-erbb3 antibodies and uses thereof |
| TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| KR20200039028A (ko) * | 2011-10-11 | 2020-04-14 | 사노피 바이오테크놀로지, 소시에떼 빠르 악씨옹 셍쁠리피에 | 류마티스 관절염 치료를 위한 조성물 및 이의 이용방법 |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| LT2627773T (lt) | 2011-10-17 | 2017-12-27 | Regeneron Pharmaceuticals, Inc. | Pelės iškirpta sunkioji imunoglobulino grandinė |
| WO2013059548A1 (en) | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
| WO2013059426A1 (en) * | 2011-10-21 | 2013-04-25 | The Regents Of The University Of California | Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof |
| CN103059137A (zh) * | 2011-10-21 | 2013-04-24 | 神州细胞工程有限公司 | 抗hIL6R高亲和力抗体的制备及应用 |
| RU2634417C2 (ru) | 2011-10-28 | 2017-10-26 | Регенерон Фармасьютикалс, Инк. | Гуманизированные il-6 и рецептор il-6 |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| AU2012339722B2 (en) | 2011-11-14 | 2017-09-14 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A |
| US9902760B2 (en) | 2011-11-23 | 2018-02-27 | Bioven 3 Limited | Recombinant proteins and their therapeutic uses |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| KR102038974B1 (ko) | 2011-12-20 | 2019-10-31 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화 경쇄 마우스 |
| WO2013116296A1 (en) * | 2012-01-31 | 2013-08-08 | Regeneron Pharmaceuticals, Inc. | Anti-asic1 antibodies and uses thereof |
| US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| TWI613215B (zh) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| SG11201405087PA (en) | 2012-03-02 | 2014-09-26 | Regeneron Pharma | Human antibodies to clostridium difficile toxins |
| RU2683514C2 (ru) | 2012-03-06 | 2019-03-28 | Регенерон Фармасьютикалз, Инк. | Мышь с общей легкой цепью |
| MY173376A (en) | 2012-03-16 | 2020-01-21 | Regeneron Pharma | Mice that produce antigen?binding proteins with ph?dependent binding characteristics |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| DK2883449T3 (en) | 2012-03-16 | 2018-04-23 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified rodents to generate them |
| MX355944B (es) | 2012-03-16 | 2018-05-07 | Regeneron Pharma | Animales no humanos que expresan secuencias de inmunoglobulina sensibles al ph. |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN114163530B (zh) | 2012-04-20 | 2025-04-29 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| PL2858487T3 (pl) | 2012-06-12 | 2020-06-01 | Regeneron Pharmaceuticals, Inc. | Humanizowane zwierzęta inne niż ludzie z ograniczonymi loci łańcucha ciężkiego immunoglobuliny |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| WO2014031610A1 (en) | 2012-08-21 | 2014-02-27 | Sanofi | Methods for treating or preventing asthma by administering an il-4r antagonist |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| CN118286430A (zh) | 2012-09-07 | 2024-07-05 | 瑞泽恩制药公司 | 以il-4r拮抗剂治疗特应性皮炎的方法 |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JP2016502520A (ja) | 2012-11-13 | 2016-01-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗プロキネチシン受容体（ｐｒｏｋｒ）抗体およびその使用 |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| DK2840892T3 (en) | 2013-02-20 | 2018-07-23 | Regeneron Pharma | Non-human animals with modified heavy chain immunoglobulin sequences |
| CA2903696A1 (en) | 2013-03-13 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| HRP20230490T1 (hr) | 2013-03-13 | 2023-08-04 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju ograničeni repertoar lakog lanca imunoglobulina |
| EA201591762A1 (ru) | 2013-03-14 | 2015-12-30 | Ридженерон Фармасьютикалз, Инк. | Человеческие антитела к grem1 |
| WO2014159595A2 (en) | 2013-03-14 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Human antibodies to nav1.7 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| JP6442404B2 (ja) | 2013-06-11 | 2018-12-19 | 国立研究開発法人国立精神・神経医療研究センター | 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法 |
| ES3050809T3 (en) | 2013-06-21 | 2025-12-23 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| EP3564671B1 (en) | 2013-08-23 | 2021-09-29 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| HUE044747T2 (hu) | 2013-09-18 | 2019-11-28 | Regeneron Pharma | Hisztidinmódosított könnyûláncú antitestek és genetikailag módosított nem humán állati élõlények ugyanennek az elõállítására |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| CA2925723A1 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| EP3063543B1 (en) | 2013-10-31 | 2020-03-11 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| KR20160086942A (ko) | 2013-11-20 | 2016-07-20 | 리제너론 파아마슈티컬스, 인크. | Ａｐｌｎｒ 조절물질 및 이들의 용도 |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| WO2015095511A2 (en) * | 2013-12-20 | 2015-06-25 | The Scripps Research Institute | Functional antibodies that modulate cell death and related methods |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| WO2015116852A1 (en) * | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| MY178160A (en) | 2014-03-11 | 2020-10-06 | Regeneron Pharma | Anti-egfrviii antibodies and uses thereof |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| US20150266976A1 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| KR102846903B1 (ko) | 2014-03-21 | 2025-08-20 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| BR112017005110A2 (pt) | 2014-09-16 | 2018-01-23 | Regeneron Pharma | anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo, molécula isolada de ácido nucleico, composição farmacêutica, e, método para diminuir níveis de glicose no sangue ou para tratar uma condição ou doença. |
| KR102576368B1 (ko) | 2014-09-23 | 2023-09-08 | 리제너론 파마슈티칼스 인코포레이티드 | 항-il-25 항체 및 그것의 사용 |
| CA2963712A1 (en) | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
| IL294554B2 (en) | 2014-11-14 | 2023-11-01 | Regeneron Pharma | Methods for treating chronic sinusitis with nasal polyps by adding an IL-4R antagonist |
| ES2809455T3 (es) | 2014-11-17 | 2021-03-04 | Regeneron Pharma | Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20 |
| EP3226899A4 (en) * | 2014-12-02 | 2018-09-05 | Regeneron Pharmaceuticals, Inc. | Methods for treating dry eye disease by administering an il-6r antagonist |
| TWI701258B (zh) | 2014-12-19 | 2020-08-11 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| WO2016136933A1 (ja) | 2015-02-27 | 2016-09-01 | 中外製薬株式会社 | Ｉｌ－６関連疾患治療用組成物 |
| CA2979702A1 (en) | 2015-03-19 | 2016-09-22 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| KR20170135967A (ko) | 2015-04-15 | 2017-12-08 | 리제너론 파마슈티칼스 인코포레이티드 | Gdf8 억제제를 사용하여 강도 및 기능을 증가시키는 방법 |
| JP2016208934A (ja) * | 2015-05-12 | 2016-12-15 | 学校法人日本大学 | 抗イヌインターロイキン−６受容体モノクローナル抗体又は抗体フラグメント及びその利用 |
| WO2016186154A1 (ja) | 2015-05-19 | 2016-11-24 | 国立研究開発法人国立精神・神経医療研究センター | 多発性硬化症（ｍｓ）患者の新規治療適用判断方法 |
| US11174317B2 (en) | 2015-06-04 | 2021-11-16 | National Center Of Neurology And Psychiatry | Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient |
| AU2016289480C1 (en) | 2015-07-06 | 2021-10-21 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| TWI797060B (zh) | 2015-08-04 | 2023-04-01 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
| AU2016308111A1 (en) | 2015-08-18 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| ES2954153T3 (es) | 2015-12-22 | 2023-11-20 | Regeneron Pharma | Combinación de anticuerpos anti-PD-1 y anticuerpos biespecíficos anti-CD20/anti-CD3 para tratar el cáncer |
| WO2017115773A1 (ja) | 2015-12-28 | 2017-07-06 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| EP4257599A3 (en) | 2016-01-13 | 2024-01-17 | Regeneron Pharmaceuticals, Inc. | Rodents having an engineered heavy chain diversity region |
| KR20180110107A (ko) | 2016-02-16 | 2018-10-08 | 리제너론 파마슈티칼스 인코포레이티드 | 돌연변이 키뉴레니나아제 유전자를 갖는 비인간 동물 |
| KR20230093522A (ko) | 2016-03-07 | 2023-06-27 | 사노피 바이오테크놀로지 | 류마티스 관절염의 치료를 위한 조성물 및 방법 |
| EP3216461A1 (en) | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| LT3439689T (lt) | 2016-04-08 | 2021-11-10 | Regeneron Pharmaceuticals, Inc. | Hiperlipidemijos gydymo būdai angptl8 inhibitoriumi ir angptl3 inhibitoriumi |
| SG10202010155YA (en) | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| CA3015371A1 (en) * | 2016-04-20 | 2017-10-26 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for making antibodies based on use of an expression-enhancing locus |
| WO2017190079A1 (en) | 2016-04-28 | 2017-11-02 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| CN113831407B (zh) | 2016-05-20 | 2024-06-11 | 瑞泽恩制药公司 | 用于使用多个引导rna来破坏免疫耐受性的方法 |
| WO2017201731A1 (en) * | 2016-05-27 | 2017-11-30 | Beijing Vdjbio Co., Ltd. | Antibodies, composition and kits comprising same, and methods of use thereof |
| WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| WO2017214548A1 (en) | 2016-06-10 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Anti-gitr antibodies and uses thereof |
| US10633434B2 (en) | 2016-06-14 | 2020-04-28 | Regeneron Pharmaceuticals, Inc. | Anti-C5 antibodies |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| RU2656160C2 (ru) * | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| WO2018039499A1 (en) | 2016-08-24 | 2018-03-01 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| ES2994774T3 (en) | 2016-09-01 | 2025-01-31 | Regeneron Pharma | Methods for preventing or treating allergy by administering an il-4r antagonist |
| CA3037738A1 (en) | 2016-09-23 | 2018-04-12 | Regeneron Pharmaceuticals, Inc. | Bi specific anti-muc16-cd3 antibodies and anti-muc16 drug conjugates |
| EA201990781A9 (ru) | 2016-09-23 | 2019-11-27 | Анти-steap2 антитела, конъюгаты антитело-лекарственное средство и биспецифические антигенсвязывающие молекулы, которые связывают steap2 и cd3, и их применение | |
| RS66884B1 (sr) | 2016-11-04 | 2025-07-31 | Regeneron Pharma | Ne-humane životinje koje imaju konstruisani lokus imunoglobulinskog lambda lakog lanca |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| JP7133551B2 (ja) | 2016-11-17 | 2022-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法 |
| JP7071975B2 (ja) | 2016-11-29 | 2022-05-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | オピオイド嗜癖を避けるための医薬組成物 |
| KR20190091290A (ko) | 2016-11-29 | 2019-08-05 | 리제너론 파아마슈티컬스, 인크. | Ｐｒｌｒ 양성 유방암 치료 방법 |
| TWI857389B (zh) | 2016-12-01 | 2024-10-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| MA46952A (fr) | 2016-12-01 | 2019-10-09 | Regeneron Pharma | Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet |
| EP3558347B1 (en) | 2016-12-22 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| MA47456A (fr) | 2017-02-10 | 2019-12-18 | Regeneron Pharma | Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| US11851486B2 (en) | 2017-05-02 | 2023-12-26 | National Center Of Neurology And Psychiatry | Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils |
| JP6963036B2 (ja) | 2017-06-01 | 2021-11-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. | Ｂｅｔ ｖ １に対するヒト抗体およびその使用方法 |
| CA3066569A1 (en) | 2017-06-07 | 2018-12-13 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| KR20200019865A (ko) | 2017-06-22 | 2020-02-25 | 노파르티스 아게 | 암 치료에 사용하기 위한 il-1베타 결합 항체 |
| CN110914295B (zh) | 2017-06-28 | 2024-08-09 | 里珍纳龙药品有限公司 | 抗人乳头瘤病毒(hpv)抗原结合蛋白及其使用方法 |
| TW202526028A (zh) | 2017-07-06 | 2025-07-01 | 美商雷傑納榮製藥公司 | 供製備糖蛋白之細胞培養方法 |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| US20200369774A1 (en) | 2017-09-13 | 2020-11-26 | Jiangsu Hengrui Medicine Co., Ltd. | Il-6r antibody and antigen binding fragment thereof and medical use |
| AU2018341587A1 (en) | 2017-09-29 | 2020-04-23 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
| EP3698808B1 (en) | 2017-10-20 | 2025-01-01 | Hyogo College Of Medicine | Anti-il-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion |
| US11034768B2 (en) | 2017-10-30 | 2021-06-15 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an IL-4R antagonist |
| BR112020006976A2 (pt) | 2017-11-30 | 2020-10-13 | Regeneron Pharmaceuticals, Inc. | anticorpos monoclonais anti-trkb e métodos de uso |
| PT3720279T (pt) | 2017-12-05 | 2022-10-06 | Regeneron Pharma | Ratinhos tendo uma cadeia leve lambda de imunoglobulina manipulada e seus usos |
| CN120571008A (zh) | 2017-12-13 | 2025-09-02 | 瑞泽恩制药公司 | 抗c5抗体组合及其用途 |
| MX2020006508A (es) | 2017-12-18 | 2020-09-17 | Regeneron Pharma | Moleculas de union a antigeno biespecificas que se unen al receptor de leptina y/o gp130, y metodos para el uso de estas. |
| WO2019126194A1 (en) | 2017-12-18 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | Angptl8 assay and uses thereof |
| CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
| JP7372925B2 (ja) | 2018-01-26 | 2023-11-01 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | インフルエンザヘマグルチニンに対するヒト抗体 |
| MX2020008095A (es) | 2018-01-31 | 2020-09-24 | Regeneron Pharma | Sistemas y métodos para caracterizar variantes de tamaño y carga de impurezas de productos farmacológicos. |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| JP7779653B2 (ja) | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| WO2019168774A1 (en) | 2018-02-28 | 2019-09-06 | Regeneron Pharmaceuticals, Inc. | Systems and methods for identifying viral contaminants |
| IL321873A (en) | 2018-03-01 | 2025-08-01 | Regeneron Pharma | Methods for altering body composition |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| KR102503356B1 (ko) | 2018-03-19 | 2023-02-24 | 리제너론 파마슈티칼스 인코포레이티드 | 마이크로칩 모세관 전기영동 분석 및 시약 |
| CN112088166A (zh) | 2018-03-26 | 2020-12-15 | 瑞泽恩制药公司 | 抗PfRH5抗体和其抗原结合片段 |
| JP7328990B2 (ja) | 2018-04-30 | 2023-08-17 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｈｅｒ２及び／またはａｐｌｐ２に結合する抗体及び二重特異性抗原結合分子、ならびにそれらのコンジュゲート及び使用 |
| EP3790899A1 (en) | 2018-05-09 | 2021-03-17 | Regeneron Pharmaceuticals, Inc. | Anti-msr1 antibodies and methods of use thereof |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| KR20250140631A (ko) | 2018-05-17 | 2025-09-25 | 리제너론 파마슈티칼스 인코포레이티드 | 항-cd63 항체, 콘쥬게이트, 및 이의 용도 |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| EA202190056A1 (ru) | 2018-06-19 | 2021-05-28 | Ридженерон Фармасьютикалз, Инк. | АНТИТЕЛА ПРОТИВ ФАКТОРА XII/XIIa И ИХ ПРИМЕНЕНИЕ |
| SG11202012729YA (en) | 2018-06-21 | 2021-01-28 | Regeneron Pharma | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| EP3823665B1 (en) | 2018-07-19 | 2024-01-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with bcma specificity and uses thereof |
| JP7460598B2 (ja) | 2018-08-10 | 2024-04-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 膝および／または股関節痛の安全で効果的な処置用の医薬組成物 |
| KR20210049863A (ko) | 2018-08-23 | 2021-05-06 | 리제너론 파아마슈티컬스, 인크. | 항-Fc 엡실론-R1 알파 (FCERIA) 항체, FCERIA 및 CD3에 결합하는 이중특이적 항원-결합 분자 및 이들의 용도 |
| IL317123A (en) | 2018-08-27 | 2025-01-01 | Regeneron Pharma | Using Raman Spectroscopy for Downstream Purification |
| MX2021002422A (es) | 2018-08-29 | 2021-07-15 | Regeneron Pharma | Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide. |
| TWI866924B (zh) | 2018-08-30 | 2024-12-21 | 美商再生元醫藥公司 | 用於將蛋白質複合物定特徵之方法 |
| AU2019368196A1 (en) | 2018-10-23 | 2021-03-18 | Regeneron Pharmaceuticals, Inc. | Anti-NPR1 antibodies and uses thereof |
| EP3876989A4 (en) | 2018-11-09 | 2022-12-07 | University of Massachusetts | Anti-cfae antibodies and methods of use |
| KR20210093856A (ko) | 2018-11-21 | 2021-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-스타필로코쿠스 항체 및 이의 사용 |
| EP3898695A1 (en) | 2018-12-19 | 2021-10-27 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof |
| AU2019405747A1 (en) | 2018-12-19 | 2021-06-17 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-CD28 x anti-CD22 antibodies and uses thereof |
| US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
| WO2020146239A1 (en) * | 2019-01-07 | 2020-07-16 | Celledit Llc | Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy |
| EP3857237B1 (en) | 2019-01-16 | 2023-03-01 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing disulfide bonds |
| TW202521583A (zh) | 2019-01-31 | 2025-06-01 | 法商賽諾菲生物技術公司 | 用於治療幼年原發性關節炎之組成物及方法 |
| CN113412121A (zh) | 2019-02-12 | 2021-09-17 | 瑞泽恩制药公司 | 使用双特异性抗体结合补体和靶抗原的组合物和方法 |
| AU2020224136C1 (en) | 2019-02-21 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Methods of treating ocular cancer using anti-MET antibodies and bispecific antigen binding molecules that bind MET |
| WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| PH12021552300A1 (en) | 2019-03-22 | 2022-07-04 | Regeneron Pharma | EGFR x CD28 MULTISPECIFIC ANTIBODIES |
| AU2020270966B2 (en) | 2019-04-10 | 2025-05-15 | Regeneron Pharmaceuticals, Inc. | Human antibodies that bind ret and methods of use thereof |
| TW202106712A (zh) | 2019-04-24 | 2021-02-16 | 美商再生元醫藥公司 | 類風溼性關節炎之診斷及治療方法 |
| CA3138306A1 (en) | 2019-05-01 | 2020-11-05 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| US20200363400A1 (en) | 2019-05-13 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Competitive Ligand Binding Assays |
| MA56116A (fr) | 2019-06-04 | 2022-04-13 | Stefano Fiore | Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde |
| AU2020289554A1 (en) | 2019-06-05 | 2021-11-18 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
| KR20220019755A (ko) | 2019-06-11 | 2022-02-17 | 리제너론 파마슈티칼스 인코포레이티드 | PcrV에 결합하는 항-PcrV 항체, 항-PcrV 항체를 포함하는 조성물, 및 이의 사용 방법 |
| US20220275088A1 (en) * | 2019-06-14 | 2022-09-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| AU2020291946A1 (en) * | 2019-06-14 | 2022-01-06 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| JP2022537555A (ja) | 2019-06-20 | 2022-08-26 | 武田薬品工業株式会社 | ウイルスベースの遺伝子療法による治療方法 |
| EP3999114A1 (en) | 2019-07-16 | 2022-05-25 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4r antagonist |
| AU2020316516A1 (en) | 2019-07-24 | 2022-02-17 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with MAGE-A4 specificity and uses thereof |
| JP7750828B2 (ja) | 2019-09-16 | 2025-10-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 免疫ｐｅｔ撮像のための放射標識されたｍｅｔ結合タンパク質 |
| KR20220066393A (ko) | 2019-09-24 | 2022-05-24 | 리제너론 파아마슈티컬스, 인크. | 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| PH12022550963A1 (en) | 2019-10-28 | 2023-09-25 | Regeneron Pharma | Anti-hemagglutinin antibodies and methods of use thereof |
| EP4065086B1 (en) | 2019-11-25 | 2026-01-28 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| MX2022006812A (es) | 2019-12-06 | 2022-08-25 | Sanofi Biotechnology | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |
| US11919965B2 (en) | 2019-12-06 | 2024-03-05 | Regeneron Pharmaceuticals, Inc. | Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies |
| KR20220119446A (ko) | 2019-12-23 | 2022-08-29 | 사노피 바이오테크놀로지 | Il-33 길항제 및/또는 il-4r 길항제를 투여하여 알레르기성 천식을 치료 또는 예방하는 방법 |
| BR112022014212B1 (pt) | 2020-01-21 | 2024-01-23 | Regeneron Pharmaceuticals, Inc | Métodos de análise de uma amostra incluindo uma proteína de interesse |
| US20230390391A1 (en) | 2020-01-22 | 2023-12-07 | Regents Of The University Of Minnesota | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| AU2021219671A1 (en) | 2020-02-10 | 2022-07-14 | Regeneron Pharmaceuticals, Inc. | Anti-Tmprss2 Antibodies and Antigen-Binding Fragments |
| MX2022009769A (es) | 2020-02-11 | 2022-11-09 | Regeneron Pharma | Anticuerpos anti-acvr1 y usos de los mismos. |
| US11958910B2 (en) | 2020-02-28 | 2024-04-16 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind HER2, and methods of use thereof |
| EP4114859A1 (en) | 2020-03-06 | 2023-01-11 | Regeneron Pharmaceuticals, Inc. | Anti-gitr antibodies and uses thereof |
| JP7116256B1 (ja) | 2020-04-02 | 2022-08-09 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片 |
| IL297836A (en) * | 2020-05-06 | 2023-01-01 | Sorrento Therapeutics Inc | Neutralizing antibodies that bind the sars-cov-2 s protein |
| IL298099A (en) | 2020-05-12 | 2023-01-01 | Regeneron Pharma | Anti-glp1r antagonist antibodies and methods of use thereof |
| JP7525762B2 (ja) * | 2020-05-18 | 2024-07-31 | ビオシオン インコーポレイテッド | Ｉｌ６ｒに結合する抗体及びその使用 |
| IL298088A (en) | 2020-05-26 | 2023-01-01 | Sanofi Biotechnology | The compositions containing an antibody against the interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using them |
| CA3179819A1 (en) | 2020-05-26 | 2021-12-02 | Alina Baum | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| EP4157450A1 (en) | 2020-05-29 | 2023-04-05 | Sanofi Biotechnology | Compositions and methods for treating noninflammatory pain in subjects with rheumatoid arthritis |
| US20230227539A1 (en) * | 2020-06-16 | 2023-07-20 | Hifibio (Hk) Limited | Methods and compositions related to neutralizing antibodies against human coronavirus |
| US20230416343A1 (en) * | 2020-08-07 | 2023-12-28 | Sorrento Therapeutics, Inc. | Neutralizing Antibodies that Bind the SARS-COV-2 S Protein |
| EP4200017A1 (en) | 2020-08-20 | 2023-06-28 | Regeneron Pharmaceuticals, Inc. | Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists |
| US20220064270A1 (en) | 2020-08-26 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| WO2022047108A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| IL301137A (en) | 2020-09-11 | 2023-05-01 | Regeneron Pharma | Identification and production of antigen-specific antibodies |
| WO2022061098A1 (en) | 2020-09-18 | 2022-03-24 | Regeneron Pharmaceuticals, Inc. | Antigen-binding molecules that bind cd38 and/or cd28, and uses thereof |
| EP4225436A1 (en) | 2020-10-05 | 2023-08-16 | Sanofi Biotechnology | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| NZ797493A (en) | 2020-10-22 | 2024-05-31 | Regeneron Pharma | Anti-fgfr2 antibodies and methods of use thereof |
| JP2023551446A (ja) | 2020-11-25 | 2023-12-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 非水膜乳化を使用した持続放出製剤 |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| US12325752B2 (en) | 2020-12-18 | 2025-06-10 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to NPR1 agonists |
| US20240317849A1 (en) | 2020-12-23 | 2024-09-26 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| CA3202197A1 (en) | 2021-01-20 | 2022-07-28 | Reginald Smith | Methods of improving protein titer in cell culture |
| WO2022187323A1 (en) | 2021-03-03 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Systems and methods for quantifying and modifying protein viscosity |
| WO2022187626A1 (en) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments |
| JP2024519407A (ja) | 2021-03-26 | 2024-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 混合プロトコルを作成するための方法およびシステム |
| BR112023021256A2 (pt) | 2021-04-20 | 2023-12-12 | Regeneron Pharma | Anticorpos humanos para artemina e métodos de uso dos mesmos |
| MX2023013075A (es) | 2021-05-04 | 2024-01-08 | Regeneron Pharma | Receptores de antígenos quiméricos con especificidad para mage-a4 y usos de estos. |
| BR112023022878A2 (pt) | 2021-05-04 | 2024-01-23 | Regeneron Pharma | Agonistas do receptor fgf21 multiespecíficos e seus usos |
| CN117730099A (zh) | 2021-05-11 | 2024-03-19 | 瑞泽恩制药公司 | 抗tmprss6抗体及其用途 |
| AU2022286617A1 (en) | 2021-06-01 | 2023-12-21 | Les Laboratoires Servier | Anti-nkg2a antibodies and compositions |
| AU2022286340A1 (en) | 2021-06-01 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| KR20240042267A (ko) | 2021-07-05 | 2024-04-01 | 리제너론 파마슈티칼스 인코포레이티드 | 항원에 대한 항체 반응을 형성하기 위한 항체의 이용 |
| BR112024000744A2 (pt) | 2021-07-14 | 2024-04-30 | Regeneron Pharma | Anticorpos de glicoprotéina spike anti-sars-cov-2 e fragmentos de ligação a antígeno |
| US20230146317A1 (en) | 2021-07-26 | 2023-05-11 | Sanofi Biotechnology | Methods for treating chronic spontaneous urticaria by administering an il-4r antagonist |
| WO2023039457A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | A high-throughput and mass-spectrometry-based method for quantitating antibodies and other fc-containing proteins |
| CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
| US20230110811A1 (en) | 2021-10-07 | 2023-04-13 | Regeneron Pharmaceuticals, Inc. | pH METER CALIBRATION AND CORRECTION |
| KR20240090311A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | pH 모델링 및 제어 시스템 및 방법 |
| CA3235380A1 (en) | 2021-10-20 | 2023-04-27 | Elizabeth Laws | Methods for treating prurigo nodularis by administering an il-4r antagonist |
| AU2022368930A1 (en) | 2021-10-22 | 2024-05-02 | Regeneron Pharmaceuticals, Inc. | Factor xi a2 domain-binding antibodies and methods of use thereof |
| MX2024005090A (es) | 2021-10-26 | 2024-07-19 | Regeneron Pharma | Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas. |
| EP4433500A1 (en) | 2021-11-19 | 2024-09-25 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
| IL313265A (en) | 2021-12-06 | 2024-08-01 | Regeneron Pharma | Antagonistic antibodies against NPR1 and methods of using them |
| CA3245647A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | METHODS AND SYSTEMS FOR ANALYZING POLYPEPTIDE VARIANTS |
| WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
| US20240002491A1 (en) | 2022-04-27 | 2024-01-04 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
| US20230416396A1 (en) | 2022-05-18 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| MA71452A (fr) | 2022-07-12 | 2025-04-30 | Regeneron Pharmaceuticals, Inc. | Anticorps dirigés contre le récepteur du facteur neurotrophique ciliaire (cntfr) et leurs procédés d'utilisation |
| JP2025528456A (ja) | 2022-08-29 | 2025-08-28 | サノフィ・バイオテクノロジー | Ｉｌ－４ｒアンタゴニストの投与による慢性誘発性寒冷蕁麻疹の治療方法 |
| KR20250103634A (ko) | 2022-11-07 | 2025-07-07 | 리제너론 파아마슈티컬스, 인크. | 인자 xi 촉매 도메인 결합 항체 및 이의 사용 방법 |
| WO2024107752A2 (en) | 2022-11-15 | 2024-05-23 | Onestone Therapeutics Llc | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| WO2024130165A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| JP2026500269A (ja) | 2022-12-16 | 2026-01-06 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | クロマトグラフィーカラムの完全性を評価するための方法及びシステム |
| AU2024207469A1 (en) | 2023-01-13 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2024158961A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Mass spectrometry-based characterization of antibodies co-expressed in vivo |
| WO2024158880A1 (en) | 2023-01-25 | 2024-08-02 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| IL322397A (en) | 2023-02-13 | 2025-09-01 | Regeneron Pharma | Treating muscle-related disorders with anti-human CACNG1 antibodies |
| EP4665410A1 (en) | 2023-02-17 | 2025-12-24 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| US20240280551A1 (en) | 2023-02-22 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | System suitability parameters and column aging |
| WO2024197119A1 (en) | 2023-03-22 | 2024-09-26 | Sanofi Biotechnology | Methods for treating chronic obstructive pulmonary disease (copd) by administering an il-4r antagonist |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| KR20260007578A (ko) | 2023-05-02 | 2026-01-14 | 리제너론 파마슈티칼스 인코포레이티드 | 항-인간 m-카드헤린(cdh15) 항체, 접합체, 및 유전자 페이로드를 근육 세포에 전달하기 위한 이들의 용도 |
| WO2024259206A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| TW202519559A (zh) | 2023-07-10 | 2025-05-16 | 美商再生元醫藥公司 | 雙特異性PD-L1xCD28抗體及其使用方法 |
| CN119285767B (zh) * | 2023-07-10 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 抗白介素-6抗体、检测白介素-6的试剂和试剂盒 |
| AU2024287529A1 (en) | 2023-07-10 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Bispecific pd-l1x4-1bb antibodies and methods of use thereof |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| AU2024291721A1 (en) | 2023-07-19 | 2026-01-22 | Regeneron Pharmaceuticals, Inc. | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| US20250109905A1 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| WO2025085594A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| TW202535934A (zh) | 2023-11-02 | 2025-09-16 | 美商再生元醫藥公司 | 利用應力來降低脂酶活性的方法 |
| WO2025149846A1 (en) | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist |
| WO2025149845A1 (en) | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025221640A1 (en) | 2024-04-15 | 2025-10-23 | Sanofi Biotechnology | Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| US20260000758A1 (en) | 2024-06-28 | 2026-01-01 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind gdf8 and activin a and uses thereof |
| US20260014252A1 (en) | 2024-07-11 | 2026-01-15 | Regeneron Pharmaceuticals, Inc. | GPRC5D x CD28 Bispecific Antibodies and Methods of Use Thereof |
| WO2026025028A1 (en) | 2024-07-26 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Methods of making ultra-high concentrated protein formulations using lyophilization |
| CN119775414B (zh) * | 2025-03-12 | 2025-06-06 | 武汉伊莱瑞特生物科技股份有限公司 | 抗猴白介素-6单克隆抗体、酶联免疫检测试剂盒及其应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| JP2998976B2 (ja) * | 1989-07-20 | 2000-01-17 | 忠三 岸本 | ヒトインタ―ロイキン―６レセプターに対する抗体 |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JPH05227970A (ja) * | 1992-02-19 | 1993-09-07 | Chugai Pharmaceut Co Ltd | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| JP3370324B2 (ja) * | 1991-04-25 | 2003-01-27 | 中外製薬株式会社 | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| FR2694767B1 (fr) * | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
| AU687763B2 (en) | 1992-10-20 | 1998-03-05 | Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service | Interleukin-6 receptor antagonists |
| US5888511A (en) | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| AU7967294A (en) * | 1993-10-06 | 1995-05-01 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| CZ296919B6 (cs) | 1994-10-07 | 2006-07-12 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutický prípravek pro lécení chronické revmatické artritidy |
| CZ296979B6 (cs) | 1994-10-21 | 2006-08-16 | Chugai Seiyaku Kabushiki Kaisha | Farmaceutický prípravek pro prevenci nebo lécení Castlemanovy nemoci |
| DE69525971T3 (de) | 1994-12-29 | 2013-01-10 | Chugai Seiyaku K.K. | Verwendung eines pm-1 antikörpers oder eines mh 166 antikörpers zur verstärkung des anti-tumor-effektes von cisplatin oder carboplatin |
| AU693318B2 (en) | 1995-02-13 | 1998-06-25 | Chugai Seiyaku Kabushiki Kaisha | Muscle protein decomposition inhibitor containing IL-6 receptor antibody |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US5785965A (en) | 1996-05-15 | 1998-07-28 | The Board Of Trustees Of The Leland Stanford Junior Univ. | VEGF gene transfer into endothelial cells for vascular prosthesis |
| AU3276297A (en) | 1996-06-27 | 1998-01-14 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| KR20080027967A (ko) | 1997-08-15 | 2008-03-28 | 츄가이 세이야꾸 가부시키가이샤 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는전신성 홍반성 낭창의 예방 및/또는 치료제 |
| US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| ES2299241T3 (es) | 1998-03-17 | 2008-05-16 | Chugai Seiyaku Kabushiki Kaisha | Preventivos o remedios para enfermedades intestinales inflamatorias que contienen anticuerpos antagonistas del receptor il-6. |
| PT1108435E (pt) | 1998-08-24 | 2007-04-30 | Chugai Pharmaceutical Co Ltd | Agentes preventivos ou terapêuticos para pancreatite contendo antagonistas da il-6 como ingrediente activo |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| EP1314437B1 (en) | 2000-08-11 | 2014-06-25 | Chugai Seiyaku Kabushiki Kaisha | Stabilized antibody-containing preparations |
| EP1327681A4 (en) | 2000-10-20 | 2004-09-01 | Chugai Pharmaceutical Co Ltd | Degraded agonist antibodies |
| EP1334731B1 (en) | 2000-10-25 | 2008-02-27 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist |
| AU2000279625A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blood mmp-3 level-lowering agent containing il-6 antgonist as the active ingredient |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| PL213311B1 (pl) | 2002-02-14 | 2013-02-28 | Chugai Pharmaceutical Co Ltd | Preparat roztworu zawierajacego przeciwcialo |
| US20060078533A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US20060275294A1 (en) | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078532A1 (en) | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060078531A1 (en) | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| EP1536012A4 (en) * | 2002-08-30 | 2006-03-08 | Chemo Sero Therapeut Res Inst | HUMAN-TYPE ANTIHUMAN INTERLEUKIN-6 ANTIBODY ANTIBODY ANTIBODY FRAGMENT |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| CA2539061A1 (en) | 2003-09-22 | 2005-03-31 | Biovation Gmbh & Co. Kg | Use of an antagonist of il-6 for treating il-6-mediated diseases |
| US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| WO2005080429A2 (en) | 2004-02-11 | 2005-09-01 | Warner-Lambert Company Llc | Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies |
| US20070036788A1 (en) | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| JPWO2006046661A1 (ja) | 2004-10-28 | 2008-05-22 | 国立大学法人大阪大学 | インターロイキン−６阻害剤 |
| BRPI0517202A (pt) | 2004-12-16 | 2008-09-30 | Genentech Inc | método de tratamento de um distúrbio autoimune, uso de um agonista de tccr, métodos para aumentar a expressão de il-10 e de socs3 em linfócitos, método para a seleção de agonistas tccr, anticorpo monoclonal, linhagem celular de hibridoma, métodos de tratamento ou supressão de uma resposta imune e método de inibição da produção de il-17, il-6 ou gm-csf |
| CN101146554B (zh) * | 2005-01-27 | 2012-10-10 | 加州大学评议会 | 中和肉毒杆菌神经毒素的治疗性单克隆抗体 |
| MX2008014804A (es) * | 2006-06-02 | 2009-01-27 | Regeneron Pharma | Anticuerpos de afinidad elevada a receptor de il-6 humano. |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| JP2010500876A (ja) | 2006-08-18 | 2010-01-14 | アブリンクス エン．ヴェー． | Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド |
| RU2319351C1 (ru) * | 2006-09-13 | 2008-03-20 | Олег Иванович Квасенков | Способ подготовки к хранению яблок свежих специального назначения |
| US20100129354A1 (en) | 2006-10-27 | 2010-05-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| EP2164873B2 (en) | 2007-05-31 | 2018-09-12 | Genmab A/S | Stable igg4 antibodies |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
-
2007
- 2007-06-01 MX MX2008014804A patent/MX2008014804A/es active IP Right Grant
- 2007-06-01 NZ NZ587107A patent/NZ587107A/en unknown
- 2007-06-01 AT AT07777380T patent/ATE537190T1/de active
- 2007-06-01 JP JP2009513324A patent/JP5307708B2/ja active Active
- 2007-06-01 MY MYPI2012001581A patent/MY159787A/en unknown
- 2007-06-01 PL PL11171039T patent/PL2374818T3/pl unknown
- 2007-06-01 HR HR20120175T patent/HRP20120175T1/hr unknown
- 2007-06-01 BR BRPI0712224A patent/BRPI0712224B8/pt active IP Right Grant
- 2007-06-01 ES ES11171039T patent/ES2398076T3/es active Active
- 2007-06-01 PT PT07777380T patent/PT2041177E/pt unknown
- 2007-06-01 RS RS20120074A patent/RS52176B/sr unknown
- 2007-06-01 CN CN200780019546XA patent/CN101454345B/zh active Active
- 2007-06-01 NZ NZ573557A patent/NZ573557A/en unknown
- 2007-06-01 RU RU2008152443/10A patent/RU2433138C2/ru active
- 2007-06-01 CA CA2652976A patent/CA2652976C/en active Active
- 2007-06-01 SI SI200730858T patent/SI2041177T1/sl unknown
- 2007-06-01 PL PL07777380T patent/PL2041177T3/pl unknown
- 2007-06-01 US US11/809,482 patent/US7582298B2/en active Active
- 2007-06-01 ME MEP-2008-853A patent/ME00519B/me unknown
- 2007-06-01 RS RS20130051A patent/RS52643B/sr unknown
- 2007-06-01 ES ES07777380T patent/ES2377579T3/es active Active
- 2007-06-01 PT PT111710398T patent/PT2374818E/pt unknown
- 2007-06-01 SI SI200731155T patent/SI2374818T1/sl unknown
- 2007-06-01 EP EP11171039A patent/EP2374818B1/en active Active
- 2007-06-01 WO PCT/US2007/013062 patent/WO2007143168A2/en not_active Ceased
- 2007-06-01 DK DK07777380.2T patent/DK2041177T3/da active
- 2007-06-01 EP EP07777380A patent/EP2041177B1/en active Active
- 2007-06-01 CN CN2012100596311A patent/CN102585002A/zh active Pending
- 2007-06-01 AU AU2007254831A patent/AU2007254831B2/en active Active
- 2007-06-01 DK DK11171039.8T patent/DK2374818T3/da active
- 2007-06-01 MY MYPI20084757A patent/MY147468A/en unknown
-
2008
- 2008-11-19 IL IL195393A patent/IL195393A/en active IP Right Grant
- 2008-11-26 CR CR10462A patent/CR10462A/es unknown
- 2008-11-28 SV SV2008003113A patent/SV2008003113A/es unknown
- 2008-12-02 TN TNP2008000502A patent/TNSN08502A1/en unknown
- 2008-12-02 GT GT200800272A patent/GT200800272A/es unknown
- 2008-12-05 KR KR1020087029749A patent/KR101464502B1/ko active Active
- 2008-12-18 NO NO20085309A patent/NO340778B1/no active Protection Beyond IP Right Term
-
2009
- 2009-07-13 US US12/501,657 patent/US8043617B2/en active Active
-
2011
- 2011-09-12 US US13/230,081 patent/US8183014B2/en active Active
-
2012
- 2012-03-07 CY CY20121100231T patent/CY1112456T1/el unknown
- 2012-04-18 US US13/450,011 patent/US20130157313A1/en not_active Abandoned
-
2013
- 2013-02-21 CY CY20131100159T patent/CY1113708T1/el unknown
- 2013-03-15 HR HRP20130228TT patent/HRP20130228T1/hr unknown
- 2013-05-15 JP JP2013102655A patent/JP5805703B2/ja active Active
-
2014
- 2014-03-12 US US14/206,259 patent/US20140255995A1/en not_active Abandoned
-
2015
- 2015-09-01 JP JP2015171640A patent/JP6140777B2/ja active Active
-
2016
- 2016-04-22 US US15/136,152 patent/US9884916B2/en active Active
-
2017
- 2017-11-13 CY CY2017039C patent/CY2017039I2/el unknown
- 2017-11-14 NO NO2017060C patent/NO2017060I1/no unknown
- 2017-11-15 NL NL300911C patent/NL300911I2/nl unknown
- 2017-11-22 LU LU00050C patent/LUC00050I2/en unknown
- 2017-11-23 LT LTPA2017038C patent/LTC2041177I2/lt unknown
- 2017-12-01 HU HUS1700050C patent/HUS1700050I1/hu unknown
- 2017-12-08 FR FR17C1057C patent/FR17C1057I1/fr active Active
-
2018
- 2018-08-31 US US16/119,695 patent/US10584173B2/en active Active
-
2020
- 2020-01-28 US US16/774,945 patent/US11370843B2/en active Active
-
2022
- 2022-05-20 US US17/749,728 patent/US20230094591A1/en not_active Abandoned
-
2024
- 2024-11-01 US US18/935,325 patent/US20250206829A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2398076T3 (es) | Anticuerpos de alta afinidad contra el receptor de IL-6 humano | |
| ES2404206T3 (es) | Anticuerpos humanos de alta afinidad dirigidos contra el receptor humano de IL-4 | |
| ES2466669T3 (es) | Anticuerpos humanos con alta afinidad para el receptor IL-4 humano | |
| ES2386480T3 (es) | Anticuerpos humanos para ligando 4 similar a delta humano | |
| JP2015508763A (ja) | ペプチドグリカン認識タンパク質１に結合する抗体 | |
| HK1173456A (en) | High affinity antibodies to human il-6 receptor |